LPTI Revenue projections taken from "The Patient InveStor"
I have a copy of the "The Patient InveStor" It is a 3 page report on LPTI. This is taken word for word.
In our opinion, this small-cap company, if successful in securing a 510(K) marketing approval from the FDA next year, could generate a revenue run of $50M in FY '01. We believe, too, that this figure could prove to be too low if internists, surgeons, or other specialists find a demonstrated-and reimbursable-need for the LDS. Using a 30 P/E multiple ,and a 40% discount rate (to compensate for the risks of owning a development stage company), yields a 1999 price target of $5.50 per share. Thus, with the stock selling for a dollar per share, we believe that the risk justifies the return. - END -
This scanning technology should play huge for everyone involved. National Health & Safety (NHLT) holds the Exclusive marketing license for the scanner. NHLT is projecting PROFITS for National Health & Safety as follows. Year #1 $4,050,000 Year #2 $18,900,000 Year #3 $54,000,000 Year #4 $108,000,000 . Bottom line, both companies, (NHLT and LPTI), will make some nice profits over the next few years from this technology alone. Do your own DD and then decide if you would like to own a piece of these companies. |
